Ruth Atherton (Ph.D. ’99, J.D.), assistant general counsel at Genentech (Roche), has been awarded the 2026 Weill Cornell Graduate School Alumni Award of Distinction.
Since 1997, the Weill Cornell Graduate School of Medical Sciences has presented this award to alumni who have distinguished themselves through outstanding contributions to biomedical research in education, focusing on science and scholarship, leadership, mentoring and teaching, and service to society.
Dr. Atherton was honored with the award on May 14 at Weill Cornell Medicine’s 2026 commencement ceremony. It recognizes her impact as a science-informed legal representative and philanthropist who serves on the boards of directors for both nonprofit organizations focused on global health equity and for startups driving innovative research.
“This award is incredibly humbling,” says Dr. Atherton, who has also held senior counsel roles at pharmaceutical companies Sanofi and Genzyme. “Weill Cornell is where I learned to think rigorously, to use data-driven analysis and to solve complex problems.”
At Weill Cornell Graduate School of Medical Sciences, Dr. Atherton became increasingly interested in the role patents played in translating innovations into medicines. After completing her Ph.D., she took a job as a scientific advisor while pursuing her J.D. from Fordham University School of Law. “I didn't see it as leaving science,” says Dr. Atherton. “I became a translator between the scientists who were making these incredible discoveries and the lawyers who were protecting those inventions and creating real-world applications for them.”
Throughout her career, Dr. Atherton has applied that idea across industry and global health. “Health impact became the focus and guiding star of my career,” she says.
At the Bill & Melinda Gates Foundation, she worked on efforts to address global health emergencies such as Ebola virus and COVID-19 and “used intellectual property to help accelerate access to testing, vaccines, treatments and health innovation instead of using it as a barrier to access.”
In her current role at Genentech, Dr. Atherton creates and supports partnerships with companies, research institutes, scientists and entrepreneurs to help Genentech and Roche deliver accessible and innovative treatments to patients.
Dr. Atherton’s path to science began long before her formal training. Growing up in Maine, she spent her time exploring the natural world with her father, a self-taught science enthusiast. “He developed a natural curiosity in me about the world,” she says, recalling their time by the ocean, where her father would teach her about nature. “It wasn't academic, but it was something that really bonded us together and carried forward my entire life.”
Her curiosity led her to Weill Cornell, where she earned a Ph.D. in cell biology and genetics and developed the scientific foundation that would guide her career. During her training, she began to see science in a broader context. “I started understanding that science is not an isolated, academic exercise,” says Dr. Atherton. “Rather, it is a foundation for a much larger pipeline that leads to innovations for human health.”
That mission has also taken on personal meaning. Recently, her husband underwent cancer treatment and received two Genentech medicines for his care. “It gave me entirely different perspective on the importance of our work” she says, “not only for my own family, but for the millions of families we impact every year.”
Looking ahead, Dr. Atherton encourages students to embrace interdisciplinary paths. “The future is multidisciplinary. Science convergence is already a reality,” she says. “I would advise students not to be afraid to follow their curiosity outside of the lab, because their skills are just as applicable to private-sector, non-profits and government, as they are to academia.”